Eearly loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries
Adult
Male
Asia
Adolescent
International Cooperation
Antiretroviral Therapy
610
HIV Infections
Health Services Accessibility
03 medical and health sciences
0302 clinical medicine
Risk Factors
Antiretroviral Therapy, Highly Active
616
Humans
Highly Active
Developing Countries
Primary Care
Proportional Hazards Models
Public Health Informatics
*HIV-1
South America
Continuity of Patient Care
Middle Aged
Patient Acceptance of Health Care
CD4 Lymphocyte Count
3. Good health
Logistic Models
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
Africa
HIV-1
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Female
Health Services Research
*Developing Countries
Public aspects of medicine
RA1-1270
Program Evaluation
DOI:
10.2471/blt.07.044248
Publication Date:
2008-09-01T12:29:04Z
AUTHORS (1)
ABSTRACT
Objective To analyse the early loss of patients to antiretroviral therapy (ART) programmes in resource-limited settings.Methods Using data on 5491 adult starting ART (median age 35 years, 46% female) 15 treatment Africa, Asia and South America with ³ 12 months follow-up, we investigated risk factors for no follow-up after initiation, or death first 6 months.Findings Overall, 211 (3.8%) had 880 (16.0%) were lost 141 (2.6%) known have died months.The probability was higher 2003-2004 than 2000 earlier (odds ratio, OR: 5.06; 95% confidence interval, CI: 1.28-20.0),as (hazard HR: 7.62; 4.55-12.8)but not recorded (HR: 1.02; 0.44-2.36).Compared a baseline CD4-cell count 50 cells/µl, < 25 cells/µl associated (OR: 2.49; 1.43-4.33),loss 1.48; 1.23-1.77)and 3.34; 2.10-5.30).Compared free treatment, fee-for-service 3.71; 0.97-16.05)and mortality 4.64; 1.11-19.41).Conclusion Early patient losses increasingly common when scaled up fee service advanced immunodeficiency at baseline.Measures maximize programme retention are required resource-poor countries.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (233)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....